Industry
Biotechnology
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Loading...
Open
356.71
Mkt cap
7.6B
Volume
454K
High
356.71
P/E Ratio
-14.01
52-wk high
368.29
Low
343.00
Div yield
N/A
52-wk low
134.90
Portfolio Pulse from
November 07, 2024 | 6:15 pm
Portfolio Pulse from
November 06, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 7:25 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 6:27 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 2:11 pm
Portfolio Pulse from Benzinga Insights
October 31, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Insights
October 31, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:05 am
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 12:19 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.